Overview

Vadadustat for the Prevention and Treatment of Acute Respiratory Distress Syndrome (ARDS) in Hospitalized Patients With Coronavirus Disease 2019 (COVID-19)

Status:
Recruiting

Trial end date:
2023-12-31

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the efficacy of vadadustat for the prevention and treatment of acute respiratory distress syndrome (ARDS) in hospitalized patients with Coronavirus Disease 2019 (COVID-19).

Phase:

Phase 2

Details

Lead Sponsor:

The University of Texas Health Science Center, Houston

Collaborators:

Akebia Therapeutics Inc.
United States Department of Defense